February 3, 2020

Jacob Chacko, M.D.
President and Chief Executive Officer
Oric Pharmaceuticals, Inc.
240 E. Grand Ave, 2nd Floor
South San Francisco, CA 94080

       Re: Oric Pharmaceuticals, Inc.
           Amendment No. 1 to Draft Registration Statement on Form S-1
           Submitted January 24, 2020
           CIK No. 0001796280

Dear Dr. Chacko:

      We have reviewed your amended draft registration statement and have the
following
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances
or do not
believe an amendment is appropriate, please tell us why in your response.

      After reviewing the information you provide in response to these comments
and your
amended draft registration statement or filed registration statement, we may
have additional
comments.

Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted January
24, 2020

Prospectus summary
Overview, page 1

1.     We note your response to prior comment 2, and we reissue in part. We do
not object to a
       discussion of these programs in the summary or in the business section,
but discovery
       research programs that do not appear material to your business and the
offering should not
       be prominently highlighted. To the extent that you believe one or more
of the discovery
       research programs is material to your business and the offering, please
revise to disclose
       the known information about these programs in your business section so
that investors
 Jacob Chacko, M.D.
Oric Pharmaceuticals, Inc.
February 3, 2020
Page 2
      will have a basis to understand these programs and the market potential.
Alternatively,
      please revise your presentation so that it does not prominently highlight
these programs in
      the Summary.
Background on cancer resistance, page 108

2.    We note your response to prior comment 11. The disclosure implies that
your product
      candidates that target innate resistance will be approved and that the
process will be easier
      or faster than the approval process for other entities. Although other
drugs targeting
      innate resistance have been approved, your product is still distinct from
prior products
      approved by the FDA. While it is appropriate for you to discuss the
successes of other
      drugs that have targeted innate resistance, please revise your disclosure
to remove any
      implications that your product candidates will be approved, are more
likely to receive
      FDA approval, or will be approved quickly.
       You may contact Ibolya Ignat at 202-551-3636 or Kevin Vaughn at
202-551-3494 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jeffrey Gabor at 202-551-2544 or Celeste Murphy at 202-551-3257 with
any other
questions.



                                                            Sincerely,
FirstName LastNameJacob Chacko, M.D.
                                                            Division of
Corporation Finance
Comapany NameOric Pharmaceuticals, Inc.
                                                            Office of Life
Sciences
February 3, 2020 Page 2
cc:       Melissa Rick, Esq.
FirstName LastName